CJC-1295 (NO DAC)

CJC-1295 (No DAC) is a research peptide related to growth hormone-releasing hormone (GHRH), the signaling molecule that helps regulate growth-hormone release from the pituitary. Researchers study the No-DAC form to examine this signaling without the extended-action DAC modification.

More specifically, research involving CJC-1295 (No DAC) examines GHRH-receptor activity, pituitary signaling, growth-hormone release, peptide structure, and the broader growth hormone / IGF-1 research axis.

Technical Identity: CJC-1295 (No DAC) is commonly characterized as a modified GHRH(1-29)-related peptide without the Drug Affinity Complex (DAC) extension used in longer-acting CJC-1295 forms.

Azyven Research CJC-1295 (No DAC) is supplied exclusively for laboratory research and analytical use.

What is CJC-1295 (No DAC)?

CJC-1295 (No DAC) is a synthetic GHRH-related research peptide. The “No DAC” designation distinguishes this form from longer-acting CJC variants that incorporate a Drug Affinity Complex designed to extend persistence.

Why is CJC-1295 (No DAC) studied?

CJC-1295 (No DAC) has attracted research interest because GHRH is one of the body's central signals for growth-hormone release from the pituitary.

Researchers study GHRH-related peptides to understand receptor activation, hormone-release patterns, peptide stability, and downstream signaling involving IGF-1 and other endocrine processes.

What research areas are associated with CJC-1295 (No DAC)?

GHRH-Receptor Research
CJC-1295 (No DAC) is studied in connection with activation of the GHRH receptor.

Growth-Hormone Signaling Research
Research examines how GHRH-related signals influence pituitary growth-hormone release.

Growth Hormone / IGF-1 Axis Research
Researchers investigate downstream endocrine signaling associated with growth-hormone activity.

Peptide-Structure Research
The No-DAC form is useful for studying how structural modifications influence peptide duration and biological behavior.

Endocrine-Signaling Research
CJC-related research contributes to broader understanding of hypothalamic-pituitary signaling and hormone regulation.

What have studies found?

Research involving CJC-related and GHRH analogues has explored receptor activity, hormone signaling, and peptide pharmacology.

GHRH-receptor activity
Studies support the use of GHRH analogues as tools for investigating pituitary growth-hormone signaling.

Growth-hormone and IGF-1 signaling
Research on CJC compounds has reported changes involving growth hormone and downstream IGF-1 biology.

Peptide duration
Studies of CJC variants demonstrate that structural modifications can substantially affect how long related peptides persist and signal.

Evidence context
DAC-modified CJC-1295 and No-DAC forms are not interchangeable, so findings involving one molecular form should not automatically be attributed to the other.

How does CJC-1295 (No DAC) relate to other Azyven products?

CJC-1295 (No DAC) is available as a standalone research peptide and is also a component of Azyven's CJC-1295 / Ipamorelin Blend.

Researchers may compare it with Sermorelin and Tesamorelin, which also involve GHRH-receptor biology, or with Ipamorelin, which approaches growth-hormone signaling through the ghrelin receptor.

Researchers can ask Aria Jr. to compare these signaling pathways and research formats.

What am I purchasing?

Azyven Research CJC-1295 (No DAC) is supplied as a lyophilized research material in the strength selected above.

Available Strengths: 5 mg and 10 mg
Form: Lyophilized powder
Product Type: Research Peptide
Intended Use: Laboratory research only

Research Use Only: Azyven Research products are intended for laboratory research purposes only. They are not intended for human or veterinary use, consumption, administration, or clinical application.